Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Employee Benefits topic
No spam. Unsubscribe anytime.
Weslaco hears alarm over surge in employee health claims tied to GLP‑1 drugs
Summary
A city consultant told the Weslaco City Commission that the municipal employee health plan saw a 38.3% rise in paid claims and a 142.1% loss ratio, driven largely by concentrated high‑cost claimants and sharp increases in GLP‑1 medication use; staff proposed monitoring, revisiting self‑funding and negotiating provider contracts.
Javier Lial of Valley Risk Consulting told the Weslaco City Commission on Nov. 4 that the city’s employee health plan saw total paid claims rise 38.3% year over year, with the plan ending the reporting year at a 142.1% loss ratio.
Lial said three percent of members accounted for roughly 54% of medical and pharmacy costs — about $3.6 million in claims — and singled out two GLP‑1 drugs (examples cited by the presenter) as major drivers of pharmacy spending. He said the combined spending on the identified GLP‑1 prescriptions rose from about $130,000 to $204,000 year over year, a roughly $74,500 increase.
The consultant recommended monitoring claims closely for the next three months and exploring plan changes intended to control costs, including revisiting a self‑funded model, pursuing a personal importation option for certain drugs and negotiating direct provider contracts with local urgent‑care and primary‑care providers to secure discounted fee schedules.
Commissioners pressed staff on wellness programs and multilingual outreach after Lial noted low employee participation in education and screening events. Staff said wellness offerings exist but participation has been limited, that some events have been offered only in English, and that improving bilingual outreach and access to after‑hours care could help reduce catastrophic claims.
The presentation did not propose an immediate change to plan coverage. The commission asked staff to return with additional analysis and to monitor the high‑cost claimants and pharmacy utilization before recommending formal plan design changes.
The presentation and discussion took place during the commission’s reports section and were led by Javier Lial (Valley Risk Consulting).
